Titre : Liver Meeting® 2018 - SOF/VEL/VOX Successful for Hepatitis C Virus Retreatment in Patients With and Without HIV
link : Liver Meeting® 2018 - SOF/VEL/VOX Successful for Hepatitis C Virus Retreatment in Patients With and Without HIV
Liver Meeting® 2018 - SOF/VEL/VOX Successful for Hepatitis C Virus Retreatment in Patients With and Without HIV
SOF/VEL/VOX Successful for Hepatitis C Virus Retreatment in Patients With and Without HIV
NOVEMBER 10, 2018Danielle Mroz
Treatment was also successful in patients with prior noncompletion or poor adherence to direct-acting antiviral therapy.
A fixed-dose combination therapy of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX, Vosevi, Gilead) was highly effective after 12 weeks in retreating direct-acting antiviral-experienced patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence, according to results of a new study.
Meeting Updates
Thus articles Liver Meeting® 2018 - SOF/VEL/VOX Successful for Hepatitis C Virus Retreatment in Patients With and Without HIV
that is all articles Liver Meeting® 2018 - SOF/VEL/VOX Successful for Hepatitis C Virus Retreatment in Patients With and Without HIV This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article Liver Meeting® 2018 - SOF/VEL/VOX Successful for Hepatitis C Virus Retreatment in Patients With and Without HIV the link address https://newsaninpiration.blogspot.com/2018/11/liver-meeting-2018-sofvelvox-successful.html
0 Response to "Liver Meeting® 2018 - SOF/VEL/VOX Successful for Hepatitis C Virus Retreatment in Patients With and Without HIV"
Post a Comment